March 2025 – Page 19 – Talk Bio

Actionable Insights Powered by AI

AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog

2 months ago talkbio0Tagged AbbVie, Amylin Analog, GUB014295, GUBamy, Gubra, Obesity, pharmaceutical licensing, Weight-Loss Agents

AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal

The Perfect Storm: Why 2025 Will Be the Year of GxP AI in Pharma

2 months ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, data-driven innovation, Drug Development, GxP, pharmaceutical manufacturing, Quality, regulatory

GxP AI, pharmaceutical manufacturing, regulatory compliance, data-driven innovation, quality management, drug development

BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger

2 months ago talkbio0Tagged Biochemical Pathway, BridgeBio, cancer pipeline, Helix (Snails), inhibitors, K-ras Oncogene, KRAS, Merger, Neoplasms, PI3 K pathway, ras Oncogene, SPAC

BridgeBio, oncology, SPAC merger, Helix Acquisition Corp. II, KRAS inhibitors, cancer pipeline, RAS pathway, PI3K pathway

Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial

2 months ago talkbio0Tagged Clinical Trials, Drops - Drug Form, Essential Tremor, Failure (biologic function), Praxis Precision Medicines, Prices

Praxis Precision Medicines, ulixacaltamide, essential tremor, clinical trial failure, stock price drop

Eisai Cuts 121 US Jobs in Strategic Restructuring

2 months ago talkbio0Tagged Alzheimer 's disease, Drug Industry, Eisai, Leqembi, restructuring, Surgical aspects, U.S.

Eisai, layoffs, restructuring, US operations, pharmaceutical industry, Leqembi, Alzheimer’s disease